Technical Analysis for GNCA - Genocea Biosciences, Inc.

Grade Last Price % Change Price Change
grade B 0.6949 -3.50% -0.03
GNCA closed down 3.5 percent on Friday, May 17, 2019, on approximately normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Flat Down
See historical GNCA trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
50 DMA Support Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Shooting Star Candlestick Bearish -3.50%
Volume Surge Other -3.50%
Bollinger Band Squeeze Range Contraction -3.50%
BB Squeeze + Upper Band Touch Range Contraction -3.50%
Upper Bollinger Band Touch Strength -3.50%
20 DMA Support Bullish -4.02%

Older signals for GNCA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Genocea Biosciences, Inc., a clinical stage biotechnology company, discovers and develops novel vaccines to treat infectious diseases. The company, through its proprietary discovery platform, AnTigen Lead Acquisition System (ATLAS), designs vaccines that stimulate T cell immunity. The company primarily develops GEN-003, a candidate therapeutic vaccine or immunotherapy, which is in Phase 1/2a trial to treat herpes simplex virus-2 or HSV-2 infections; and GEN-004, a T cell vaccine candidate that is in Phase 1 trial to prevent infections caused by pneumococcus. It also develops earlier-stage programs for chlamydia, HSV-2 prophylaxis, and malaria. The company, formerly known as Genocea, Inc., was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Biotechnology Medical Specialties Infectious Diseases Immunotherapy Vaccination Microbiology Infections Vaccine Herpes Simplex Herpes Simplex Virus Malaria Sexually Transmitted Diseases And Infections Herpes Simplex Research Viruses
Is GNCA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.02
52 Week Low 0.28
Average Volume 379,136
200-Day Moving Average 0.63
50-Day Moving Average 0.6936
20-Day Moving Average 0.707
10-Day Moving Average 0.7156
Average True Range 0.0531
ADX 21.1
+DI 17.8884
-DI 10.4237
Chandelier Exit (Long, 3 ATRs ) 0.6254
Chandelier Exit (Short, 3 ATRs ) 0.8193
Upper Bollinger Band 0.7463
Lower Bollinger Band 0.6677
Percent B (%b) 0.35
BandWidth 11.117398
MACD Line 0.0081
MACD Signal Line 0.0097
MACD Histogram -0.0016
Fundamentals Value
Market Cap 19.89 Million
Num Shares 28.6 Million
EPS -2.04
Price-to-Earnings (P/E) Ratio -0.34
Price-to-Sales 0.00
Price-to-Book 1.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.78
Resistance 3 (R3) 0.78 0.76 0.76
Resistance 2 (R2) 0.76 0.74 0.76 0.76
Resistance 1 (R1) 0.73 0.73 0.72 0.72 0.75
Pivot Point 0.71 0.71 0.70 0.71 0.71
Support 1 (S1) 0.67 0.69 0.67 0.67 0.64
Support 2 (S2) 0.66 0.68 0.65 0.63
Support 3 (S3) 0.62 0.66 0.63
Support 4 (S4) 0.61